U.S. heart disease patients will have access to dissolvable, impermanent stents due to the FDA approval of Abbott Laboratories' Asborb bioresorbable stent, which will enable the high-profile device to hit the market after years of clinical trials, and fierce debate over its safety and efficacy. Read More
